No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis

Julia L. Marcus,David V. Glidden,Kenneth H. Mayer,Albert Y. Liu,Susan Buchbinder,K. Rivet Amico,Vanessa McMahan,Esper G. Kallas,Orlando Montoya-Herrera,José Henrique Pilotto,Robert M. Grant

No Evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis

2013

Julia L. Marcus
David V. Glidden
Kenneth H. Mayer
Albert Y. Liu
Susan Buchbinder
K. Rivet Amico
Vanessa McMahan
Esper G. Kallas
Orlando Montoya-Herrera
José Henrique Pilotto
Robert M. Grant

Objective: Preexposure prophylaxis (PrEP) with emtricitabine/tenofovir disoproxil fumarate (FTC/TDF) reduced HIV acquisition in the iPrEx trial among men who have sex with men and transgender women. Self-reported sexual risk behavior decreased overall, but

Keywords:

Pre-exposure prophylaxis
Risk compensation
Young adult
Emtricitabine
Gynecology
Transgender
Men who have sex with men
Pregnancy
Syphilis
Internal medicine
Medicine
Rate ratio
Relative risk
Placebo
Condom

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

184

Citations